Why IMU is a multi multi bagger, page-9711

As we wind out the year with another Imugene AGM many investors are sure to look back on the year with negative sentiment having purchased IMU shares in the 30’s and 40’s, if not 50’s, only to see the stock now fall below 20 cents. No doubt they could elude to the fact communication from Imugene has been disjointed and at times fractured. Whilst the company’s prevailing lack of commercial direction may have left some wishing they had invested in companies presenting them with financial outcomes, as opposed to financial opportunities.

That said for those who have performed the necessary research Imugene could be viewed as a shrewd medium term investment off the back of the prevailing safety and efficacy exhibited in both their pre and post clinical trials. The scientific platforms owned and licensed by Imugene have been strengthened during the year through the preclinical success of the Oncarlytics program, which offers patients the promise of acquiring readily available off the shelf medication to treat an array of solid tumours, for which treatment is currently unavailable. This is a massive boon for Imugene, as many Car T and allogenic providers are limited to the treatment of blood cancers, not to mention the limitations imposed by their extraneous cost. Companies including Amgen, Celularity and Eureka have all visualised the potential their products have in combining with Imugene to produce drugs capable of reducing tumour size and tumour progression within cancer patients. The license fees affordable to Imugene for this third party access to Imugene’s Oncarlytics platform are immeasurable, particularly when one considers the breadth of players involved. Though once again Imugene needs to take the lead and commercialise these arrangements with the said beneficiaries of their platform. Up until now collaborations have been established upon nothing more than good faith, research and the swapping here and there of a few vaccine satchels.

In essence Imugene’s oncolytic viruses CF33 and the potent parent Vaxinia hold the key to the company's riches. Grossly undervalued if at all valued by investors, analysts, fund managers and the public alike, Big Pharma are soon to realise the strength of these wonder drugs. Having now proceeded through the stringent low dose regime imposed on them by the FDA, both drugs are entering the ramp up stage wherein new patients can be administered with the OV’s in larger numbers at more frequent intervals. All bodes well for these concurrent clinical trials as they enter the pointy end of Phase 1, under the supervision of the prestigious City of Hope team. Unlike many on these threads I envisage both CF33 and Vaxinia being accepted into registrational trials in 2023, given the pent up demand sure to be engendered from oncologists and cancer patients who begin to visualise a potential solution to an otherwise protracted life sentence at the hands of this dreaded disease. I for one was buoyed by Professor Yuman Fong’s recent acknowledgement of his viruses safety. This was indeed music to the ears of many long term holders who remain confident his drugs are efficacious and able to arrest the full spectrum of solid tumours within patients. If as anticipated the forthcoming OV trial results are successful, they are sure to put a rocket under all those in sight, not to mention the current share price.

Perhaps the past quarters focus on Oncarlytics and Imugene’s OV’s has if anything turned investors and the markets attention away from the company’s success in their B cell trials, including both Her Vaxx and Professor Kaumaya’s PD1 Vaxx. Both drugs have been commercialised by Imugene to the extent they have a broad patent base throughout Asia, Europe and the USA, from which they can be sold well into the late 2030’s. Her Vaxx OSR data was exceptional given the vaccine was trialed in late stage patients at only half the recommended optimal biological dose rate. Who knows what the vaccine shall achieve when administered to earlier stage cancer patients at the optimal biological dose rate, particularly when combined with a successful immunotherapy treatment such as Merck’s Keytruda. Likewise PD1 Vaxx, which can finally be treated to earlier stage lung cancer patients at its recommended biological dose rate, in combination with Roche’s successful Tercentriq vaccine. Given the fact the watered down E10 version of Her Vaxx extended life in late stage gastric cancer patients by 5.6 months, there’s sure to be a queue longer than that at the Boxing Day sales lining up for Her Vaxx on Super strength. Or for that matter any lung cancer patients who have heard of PD1 Vaxx’s success in stabilising if not eliminating the disease in some patients.

The share price is a bone of contention for many holders at this late stage of 2022, with many taking aim at the company's perceived secrecy surrounding capital raises and its failure to disclose the identity of incoming majority shareholders to the stock. I mentioned in previous posts financial leadership, the weakness of media strategy and an apparent lack of financial direction as possible reasons for the current dilemma facing share holders. Whereas investors see as positive moves by CEO’S including Eureka Therapeutics Cheng Liu to financially outline and list their wares on the broader NASDAQ exchange (i.e., see Estrella Biopharma), many cannot fathom or stomach IMU’s focus on Australia and the ASX, where prices are impeded by a small number of option renewals, institutional players, hedge funds and short sellers. Put simply Imugene just does not have the reach to command volume buying in its current state, and consistently talking of the science doesn’t cut it, for the majority of everyday investors cannot comprehend the science. The low volumes of shares traded in a company introducing ground breaking medical technology to the world is quite unbelievable. As mentioned previously influencers, prominent analysts and social media are all required for the company to remove itself from the potential clutches of Big Pharma into a deeper pool of investors, or more importantly the public at large. I cannot think of a better value proposition than that on offer from the Imugene team, though unfortunately without a media lobotomy in combination with a clear and succinct financial direction from which to move forward, the share price may continue to under perform as the market waits, and waits, and waits some more for scientific data to arrive…

Now more than ever patience, resilience, tenacity, endurance, stoicism, strength of character, a sense of belief in those developing the technology and an understanding of the fact “Rome wasn’t built in a day”, are required if we are to reap the true benefits of Imugene’s hard labour. Perhaps we should take time out to consider the ongoing efforts of our visitors, Professor Yuman Fong and Dr Saul Priceman, who have been waiting much longer than us to hit pay dirt. Keeping in mind their idea of hitting pay dirt is putting others before themselves.

Enjoy the AGM. All the best to Leslie and all the IMU team. Continue the debate. Your thoughts and opinions are important no matter how trivial or inconsequential you may think they are.

DYOR - Opinions only - Seek investment advice as and where necessary

Good luck to all long term holders, not too long to go now, the market may just catch up sooner than you think.